It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Parameswaran Venugopal, MD

  • Hematology
  • Internal Medicine
Faculty Rank: Professor
Medical or Graduate Education: University of Kerala Medical College, India
Residency: Henry Ford Hospital - Internal Medicine
  Rush University Medical Center - Internal Medicine
Fellowship: Rush University Medical Center - Hematology/Oncology
Clinical Expertise:
  • Anemia
  • Aplastic anemia
  • Blood disorders, cancerous
  • Blood disorders, noncancerous
  • Bone marrow biopsy
  • Cutaneous T-cell lymphoma (CTCL)
  • Hairy cell leukemia
  • Hodgkin lymphoma
  • Leukemias, acute and chronic
  • Multiple myeloma
  • Myelodysplastic syndrome (MDS)
  • Myeloproliferative neoplasms
  • Non-Hodgkin lymphoma
  • Targeted therapy for hematologic cancer
  • Thrombocytopenia
Research Interests:
  • Clinical trials for the treatment of hematologic malignancies
  • Factors that predict response to therapy and prognosis
  • Monoclonal antibodies and experimental drug treatments for hematologic malignancies
Languages Spoken:
  • Malayalam
Google Map
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

    Karmali R, Larson ML, Shammo JM, Basu S, Christopherson K, Borgia JA, Venugopal P
    Leuk. Lymphoma
    2015 Mar 4
  2. Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia.
    Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B
    J. Clin. Oncol.
    2015 Mar 2
  3. All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies.
    Karmali R, Dalovisio A, Borgia JA, Venugopal P, Kim BW, Szymanski KG, Hari P, Lazarus H
    Blood Rev.
    2014 Sep 28
  4. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients.
    Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd.
    J Leukoc Biol. 2013
    2013 Jan
    93(1):161-70. doi: 10.1189/jlb.0612301. Epub 2012 Nov 7.
  5. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
    Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W.
    Lancet Oncol. 2012
    2012 Nov
    13(11):1096-104. doi: 10.1016/S1470-2045(12)70436-9. Epub 2012 Oct 15.
  6. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
    Lai S, Venugopal P, Leslie W.
    Clin Adv Hematol Oncol. 2012
    2012 Feb
    10(2):134-6. No abstract available.
  7. Erdheim-Chester Disease.
    Liotta EM, Jhaveri MD, Fox JC, Venugopal P, Lewis SL.
    Arch Neurol. 2012
    2012 Aug 27:1-2. doi: 10.1001/archneurol.2012.180. [Epub ahead of print] No abstract available.
  8. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine.
    Jagan S, Paganessi LA, Frank RR, Venugopal P, Larson M, Christopherson KW 2nd.
    Adv Hematol. 2012
    2012:727683. doi: 10.1155/2012/727683. Epub 2012 Sep 23.
  9. A patient with necrobiotic xanthogranuloma presenting with an anterior mediastinal mass, plasma cell dyscrasia, and a lymphoproliferative disorder.
    Chen KY, Leslie W, Mahon B, Venugopal P.
    Clin Adv Hematol Oncol. 2011
    2011 Sep
    9(9):696-700. No abstract available.
  10. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P.
    Leuk Lymphoma. 2011
    2011 Nov
    52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24.
  11. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA.
    Clin Lymphoma Myeloma Leuk. 2011
    2011 Dec
    11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22.
  12. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
    Nabhan C, Davis N, Bitran JD, Galvez A, Fried W, Tolzien K, Foss S, Dewey WM, Venugopal P.
    Cancer. 2011
    2011 Apr 1
    117(7):1490-7. doi: 10.1002/cncr.25603. Epub 2010 Nov 8.
  13. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
    Nabhan C, Davis N, Bitran JD, Galvez A, Fried W, Tolzien K, Foss S, Dewey WM, Venugopal P.
    2010 Nov 8
  14. Clofarabine: a new treatment option for patients with acute myeloid leukemia.
    Larson ML, Venugopal P.
    Expert Opin Pharmacother. 2009
    2009 Jun
    10(8):1353-7. doi: 10.1517/14656560902997990. Review.
  15. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.
    Schuster SJ, Venugopal P, Kern JC, McLaughlin P.
    Leuk Lymphoma. 2008
    2008 Sep
    49(9):1681-92. doi: 10.1080/10428190802216731. Review.
  16. Idiopathic hemophagocytic syndrome with a fulminant clinical course.
    Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P.
    Clin Adv Hematol Oncol. 2008
    2008 Aug
    6(8):587-90. Review. No abstract available.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript